These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21418182)

  • 1. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.
    Veeger NJ; Piersma-Wichers M; Meijer K; Hillege HL
    Br J Haematol; 2011 May; 153(4):508-14. PubMed ID: 21418182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.
    Veeger NJ; Piersma-Wichers M; Tijssen JG; Hillege HL; van der Meer J
    Br J Haematol; 2005 Feb; 128(4):513-9. PubMed ID: 15686461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.
    Poli D; Antonucci E; Testa S; Tosetto A; Ageno W; Palareti G;
    Circulation; 2011 Aug; 124(7):824-9. PubMed ID: 21810658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
    van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
    PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of major bleeding after a minor bleed during treatment with vitamin K antagonists is determined by fixed common risk factors.
    van Rein N; le Cessie S; van Vliet IP; Reitsma PH; van der Meer FJ; Lijfering WM; Cannegieter SC
    J Thromb Haemost; 2016 May; 14(5):948-52. PubMed ID: 26988994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study.
    Pengo V; Legnani C; Noventa F; Palareti G;
    Thromb Haemost; 2001 Mar; 85(3):418-22. PubMed ID: 11307807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of falls and major bleeds in patients on oral anticoagulation therapy.
    Donzé J; Clair C; Hug B; Rodondi N; Waeber G; Cornuz J; Aujesky D
    Am J Med; 2012 Aug; 125(8):773-8. PubMed ID: 22840664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
    Poon IO; Lal L; Brown EN; Braun UK
    J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.
    Tincani E; Baldini P; Crowther MA; Zanasi A; Ferrari P; Cenci AM; Rioli G
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):47-51. PubMed ID: 20523164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of vitamin K antagonist overcoagulation.
    Marie I; Leprince P; Menard JF; Tharasse C; Levesque H
    QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of oral anticoagulant therapy with increasing age.
    Torn M; Bollen WL; van der Meer FJ; van der Wall EE; Rosendaal FR
    Arch Intern Med; 2005 Jul; 165(13):1527-32. PubMed ID: 16009869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic and/or bleeding complications in patients under oral anticoagulation followed at a tertiary hospital.
    Pelicano N; Branco LM; Pinto A; Sá A; Timóteo AT; Feliciano J; Fiarresga A; Agapito AF; Palma MC; Quininha J
    Rev Port Cardiol; 2005; 24(7-8):957-68. PubMed ID: 16240682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
    Abdelhafiz AH; Wheeldon NM
    Clin Ther; 2004 Sep; 26(9):1470-8. PubMed ID: 15531009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
    Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
    Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
    Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.
    Hutten BA; Prins MH; Gent M; Ginsberg J; Tijssen JG; Büller HR
    J Clin Oncol; 2000 Sep; 18(17):3078-83. PubMed ID: 10963635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.